AbbVie, CytomX to co-develop Probody drug conjugates
In its third cancer deal in two days, AbbVie Inc. is now partnering with CytomX Therapeutics Inc. to co-develop and co-commercialize Probody drug conjugates against CD71, or transferrin receptor 1 (TfR1).
- Drug Discovery Tools
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.